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ABSTRACT
Dendritic cells (DCs) are potent antigen-presenting cells capable of priming activation of naive T cells. Be-
cause of their immunostimulatory capacity, immunization with DCs presenting tumor antigens has been pro-
posed as a treatment regimen for cancer. The results from translational research studies and early clinical
trials point to the need for improvement of DC-based tumor vaccines before they become a more broadly ap-
plicable treatment modality. In this regard, studies suggest that genetic modification of DCs to express tumor
antigens and/or immunomodulatory proteins may improve their capacity to promote an antitumor response.
Because the DC phenotype is relatively unstable, nonperturbing methods of gene transfer must be employed
that do not compromise viability or immunostimulatory capacity. DCs expressing transgenes encoding tumor
antigens have been shown to be more potent primers of antitumor immunity both in vitro and in animal mod-
els of disease; in some measures of immune priming, gene-modified DCs exceeded their soluble antigen-pulsed
counterparts. Cytokine gene modification of DCs has improved their capacity to prime tumor antigen-
specific T cell responses and promote antitumor immunity in vivo. Here, we review the current status of gene-
modified DCs in both human and murine studies. Although successful results have been obtained to date in
experimental systems, we discuss potential problems that have already arisen and may yet be encountered be-
fore gene-modified DCs are more widely applicable for use in human clinical trials.
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OVERVIEW SUMMARY
This review discusses the potential benefits and limitations
of genetically modified dendritic cells (DCs) for use in ther-
apeutic antitumor vaccines. We discuss the various systems
employed for gene transfer to DCs, including the growing
consensus that viral vectors represent the most efficient
means of transduction. We also describe data supporting
the use of DCs modified to express genes encoding tumor
antigens and immunomodulatory proteins, such as cy-
tokines, to promote antitumor immunity. Successful pre-
clinical results are described, in which genetically modified
DCs are used in in vitro immunologic studies with human
cells in vitro as well as animal tumor models in vivo . We
point out the benefits and disadvantages of using gene-
modified DCs and express our viewpoint on what types of
gene-modified DCs may be considered candidates likely to
reach the clinic.
INTRODUCTION
S INCE TH EIR D ISCO VER Y more than 25 years ago, dendriticcells (DCs) have emerged as the most potent member of the
class of antigen-presenting  cells (APCs) (Banchereau and Stein-
man, 1998). Because of their potent capacity to stimulate T lym-
phocytes, particularly naive T cells, DCs have been proposed
as the basis for vaccines designed for the treatment of cancer
(Cohen et al., 1994; Schuler and Steinman, 1997). Coupled with
our understanding that tumors express antigens (TAA, tumor-
associated antigen) capable of being recognized by the immune
system, DC-based tumor vaccines have been translated from
the laboratory to the clinic (Timmerman and Levy, 1999). The
results from early phase I clinical trials support the idea that
DCs presenting TAA can initiate an antitum or immune response
in certain patients and, in some cases, can lead to partial or
complete regression of tumors (Hsu et al., 1996; Nestle et al.,
1998). Although these early results are encouraging, they also
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point to the exigency for modification of DC-based vaccines
before they become a commonly used modality for the treat-
ment of cancer. Gene therapy in the setting of DC-based vac-
cines represents one such modification. The purpose of this re-
view is to bring together data on gene techniques and
translational research using gene-m odified DCs. By drawing
parallels from animal models and in vitro assays utilizing 
human cells, we hope to highlight the promise entailed in 
creating the next generation of vaccines based on gene-
modified DCs.
DC generation and morphology
Because DCs can be derived from multiple cell types using
a number of different tissue culture conditions, a brief primer
on DC generation and phenotype is necessary before we can
begin to address issues of gene transfer. DCs are distinguished
by their dendritic, veiled morphology (Fig. 1) and high ex-
pression levels of both MHC class I and class II as well as cos-
timulatory and adhesion molecules involved in T cell activa-
tion such as CD80/CD86 and ICAM-1 (Hart, 1997; Banchereau
and Steinman, 1998). DCs reside in the spleen, lymph nodes,
and circulation but can arise from cells such as epidermal
Langerhans cells or monocytes, which react to stimuli such as
inflammatory cytokines.
An important step in the application of DCs in therapeutic
settings was the ability to obtain them in large numbers in highly
purified form from donors. In both rodents and humans, DCs
can be generated from bone marrow or peripheral blood cells;
in the case of peripheral blood both circulating CD34 1
hematopoietic progenitor cells and CD14 1 adherent monocytes
were found to give rise to DCs under defined tissue culture con-
ditions. On culture in the presence of granulocyte-ma crophage
colony-stimulati ng factor (GM-CSF) and interleukin 4 (IL-4),
the resulting cells display the veiled morphology characteristic
of DCs and express T cell stimulatory molecules such as MHC
I/II, CD80/86, and ICAM-1 (Bender et al., 1996; Romani et al.,
1996; Talmor et al., 1998). In humans, these cells represent
“immature DCs,” defined in part by their high antigen uptake.
Further culture of these cells in monocyte conditioned medium
(MCM) or with the addition of tumor necrosis factor a
(TNF- a ), lipopolysaccharid e, type I interferons (IFNs), or IL-
1 b can increase the expression of T cell stimulatory receptors
and induce expression of DC maturation markers such as CD83
(Bender et al., 1996; Luft et al., 1998). These “mature DCs”
are more potent T cell stimulators than immature DCs but have
reduced phagocytic and endocytic activities (Banchereau and
Steinman, 1998). Mature DCs are thought to be better for use
in immunization  regimens than their immature counterparts be-
cause of their increased immunostimulatory capacity, stability
of their phenotype, and increased trafficking to lymphoid or-
gans. In the mouse the distinction between immature and ma-
ture DCs is not clear-cut due, in part, to lack of a selectable
marker for maturation. However, murine bone marrow-derived
DCs (BMDCs) cultured in GM-CSF plus IL-4 are functionally
more mature (as measured by phagocytic/ endocytic activities
and T-cell stimulatory capacity) than DCs derived from GM-
CSF cultures (Talmor et al., 1998; Labeur et al., 1999). The
addition of CD40L or TRANCE, both ligands for TNF recep-
tor family members, has also been shown to promote the mat-
uration and survival of DCs (Wong et al., 1997; Kuniyoshi et
al., 1999). Taken together, it appears that multiple modes of
DC maturation are capable of resulting in a cell with high im-
munostimulato ry capacity. Whether these different sources of
DC progenitors and different protocols for DC generation re-
sult in similarly effective antigen-presentin g cells is a matter
still open to debate but should be kept in mind by the reader of
both clinical and translational research reports.
GENETIC MODIFICATION OF DENDRITIC
CELLS
Broadly defined, the target genes transferred into DCs fall
into two categories: TAA and immunomodulato ry proteins such
as cytokines. In the case of DCs expressing TAA, gene con-
structs encoding whole proteins and cytotoxic T lymphocyte
(CTL)-specif ic epitopes have been utilized. There are a num-
ber of potential advantages to using TAA gene-modified DCs.
DCs expressing TAA via a transgene should, in theory, present
antigen for a longer period than peptide or tumor lysate-pulsed
DCs, in which the duration of expression is restricted by the
half-life of the peptide–MHC complex created during antigen
pulsing. Plasmid DNA is relatively stable and easy to generate,
making it a more suitable source of antigen than whole tumor
RNA and eliminating the possible transformation of DCs by
oncogenes or tumor suppressor genes encoded in tumor DNA.
However, TAA gene-transfected DCs present only the antigen
encoded by the transgene, resulting in an antigenic restriction
not present when tumor lysate or RNA/DNA is used as the anti-
gen source. Because DCs are potent APCs, use of viral gene
vectors could result in priming of antiviral immunity, particu-
larly CTLs, resulting in elimination of transfected DCs during
subsequent rounds of immunization. Furthermore, the relative
instability of the DC phenotype necessitates a method of trans-
fection that does not compromise viability or negatively affect
DC functions (Fields et al., 1998). The challenge to the broader
use of gene-modified DCs in vaccine applications then is
twofold: determ ine the most efficient means of transfecting DCs
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FIG. 1. Photomicrogr aph of a murine dendritic cell. Typical
morphology shows a stellate appearance with multiple cell
processes. The DC was isolated from spleen as described in
Fields et al. (1998).
and the optimal target genes to be transfected. In this regard,
DCs transfected with genes encoding cytokines or T cell co-
stimulatory molecules represent APCs that are potentially more
immunostim ulatory or longer lived than unmodified DCs.
Efficient gene transfer into DCs via viral vectors
Published reports of gene-modified DCs have used a variety
of gene transfer vehicles including cationic lipids, viral vectors,
and plasmid-coated gold particles (Table 1). Gene transfer ef-
ficiencies, when reported, ranged from 5% efficiency to greater
than 95% transgene-expressi ng cells. The variation in gene
transfer efficiencies may be due, in part, to the transfection vec-
tor system employed but may also be due to modifications in
gene transfer protocols. Several laboratories have attempted to
determine which gene transfer system(s) are optimal for trans-
fecting DCs efficiently. The growing consensus is that viral vec-
tors represent a more efficient and productive means compared
with physical or chemical methods. While the majority of pub-
lished reports detailing virus-m ediated transduction efficiency
and its effect on DC phenotype have utilized adenovirus, DCs
or their progenitors have been transduced with similar effi-
ciencies in studies using retrovirus (Aicher et al., 1997),
poxvirus (Brown et al., 1999), and herpesvirus (Coffin et al.,
1998).
In direct comparisons of adenoviral vectors with physical
methods of transfection such as liposom es, electroporation and
CaPO4, viral vectors have resulted in consistently higher lev-
els of gene transfer efficiency and expression and transfection
efficiencies (90–100 versus 5–10%) (Arthur et al., 1997; Dietz
and Vuk-Pavlovic,  1998; Zhong et al., 1999). In fact, most
physical methods of transfection were toxic to DCs, resulting
in loss of phenotype and substantial cell death (Arthur et al.,
1997). Even under optimal conditions when electroporation re-
sulted in 15% transfection efficiency, viability of the DC was
less than 60% (Van Tendeloo et al., 1998), and transfection via
electroporation occurred in CD34 1 HSC-derived but not in
monocyte-derive d DCs. However, it should be noted that sub-
stantial protein production after gene gun transfection has been
achieved, although no determ ination of transfection efficiency
was determined (Tuting et al., 1998). Adenovirus titers of up
to 1000–10,000 multiplicities of infection (MOIs) could be well
tolerated by DCs as opposed to the M202 and M207 human
melanom a cell lines, which demonstrated 40–100% cell death
at the same titers (Arthur et al., 1997). Generally, no alterations
in DC phenotype after adenoviral infection have been noted
(Arthur et al., 1997; Zhong et al., 1999), although there are
some reports of increases in T cell stimulatory molecules, such
as MHC class I, CD80, and CD86, suggesting that adenovirus
may initiate DC maturation (Kaplan et al., 1999; Rea et al.,
1999). Transgene expression in adenovirus-infecte d human
DCs could persist for greater than 1 week (Arthur et al., 1997)
as opposed to gene gun-mediated transfection, which resulted
in only transient expression lasting less than 72 hr (Tuting et
al., 1997). When transgene expression from viral vectors was
lost rapidly, addition of DC survival factors such as TRANCE
could prolong reporter gene expression (although it is not
known whether this effect is due to maintenance of the trans-
gene or prolonged survival of the DCs) (Zhong et al., 1999).
Adenovirus-tran sfected DCs were either as effective (Arthur et
al., 1997; Zhong et al., 1999) stimulators of the mixed lym-
phocyte reaction (MLR) or more effective (Kaplan et al., 1999;
Rea et al., 1999) than uninfected control DCs; increased stim-
ulatory capacity accom panied increased expression of T cell
stimulatory molecules. It appears that adenovirus has been
equally capable of mediating gene transfer into human or mouse
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TABLE 1. GEN E TRAN SFER TEC HN IQUE S EM PLO Y ED IN DEN DRITIC CELL MODIFICA TIO N
Transfection vector DC source Comments References
Virus
Adenovirus Human PBMCs . 90% transduction Arthur et al. (1997);
Mouse bone marrow efficiency (MOI . 100) Zhong et al. (1999)
Poxvirus Human PBMCs Antiviral immunity does not Kim et al. (1997);
Mouse bone marrow affect in vivo efficacy Brossart et al. (1997);
Brown et al. (1999)
Retrovirus Human CD34 1 HSCs Postinfection DC maturation Aicher et al. (1997)
Mouse bone marrow required Specht et al. (1997)
Herpesvirus Human PBMCs Multiple gene transduction Coffin et al. (1998)
achieved
CD40-targeted Human PBMCs CD40 targeting resulted in DC Tillman et al. (1999)
adenovirus maturation
Liposome- Human PBMCs Efficient transduction at Dietz and Vuk-
modified MOI , 100 Pavlovic (1998)
adenovirus
Physical methods
CaPO4, liposomes Human PBMCs . 10% transfection efficiency Arthur et al. (1997);
Zhong et al. (1999)
Electroporation Human PBMCs 15% transfection efficiency, Van Tendeloo et al.
low DC viability (1998)
Biolistic device Human PBMCs Transient expression ( , 72 hr) Tuting et al. (1997)
Mouse bone marrow 5–10% transfection efficiency Tuting et al. (1998)
Abbreviations : PBMCs, Peripheral blood mononuclear cells; HSCs, hematopoietic stem cells; DC, dendritic cells.
DCs (or DC lines), although no comparative studies have yet
been reported (Arthur et al., 1997; Brossart et al., 1997; Ribas
et al., 1997; Dietz and Vuk-Pavlovic,  1998; Sonderbye et al.,
1998; Kaplan et al., 1999; Zhong et al., 1999).
The requirement for high viral titers (MOI . 100) to achieve
efficient gene transfer suggests that DCs lack the adenovirus
attachment factor Coxsackie– adenovirus receptor (CAR) or the
a v integrins, a v b 3 or a v b 5, used by the virus for fusion with its
target cell (Wickham et al., 1993; Bergelson et al., 1997, 1998).
Indeed, monocyte-derive d DCs cultured in GM-CSF and IL-4
are deficient in CAR but do express the a v integrin (Rea et al.,
1999; Tillman et al., 1999). Instead, DCs may incorporate virus
through phagocytic activity. This is consistent with the obser-
vation that gene transfer efficiency and expression levels (as
measured by green fluorescent protein [GFP] fluorescence)
were greater in immature DCs than in DCs induced to mature
by lipopolysaccharid e (LPS) or MCM (Zhong et al., 1999). This
had led some investigators to use adenovirus to enhance uptake
of conjugated DNA particles or to augment adenovirus infec-
tion with antibodies or liposomes. Successful gene transfer to
both mouse and human DCs has resulted using adenovirus to
enhance the uptake of DNA bound to chemical linkers such as
poly-L-lysine (Mulders et al., 1998), modified receptor proteins
such as transferrin (Curiel-Lewandrowski et al., 1999) and mod-
ified chemical linkers targeted to DC receptors such as man-
nosylated polyethylenimin e (Diebold et al., 1999a,b). These
systems, which used the virus to aid in DNA/conjugate uptake,
were purported to be less toxic than using high-titer adenovirus
and would result in a reduced induction of antiadenovirus im-
munity. Other investigators have attempted to modify adenovi-
ral delivery to DCs by additional strategies. In this regard, ade-
novirus targeted to CD40 or b 1 integrins on human DCs by a
bispecific antibody led to increased reporter gene (luciferase)
activity compared with adenovirus alone, even at relatively low
MOI ( , 100) (Tillman et al., 1999). Besides improving gene
transfer efficiency, addition of CD40 antibody with the aden-
ovirus had the additional benefit of delivering a possible DC
maturation signal; both IL-12 production and allo-M LR stimu-
lation were increased in CD40-targeted  adenovirus DC prepa-
rations (Tillman et al., 1999). Improved gene transfer efficiency
was also seen when adenovirus were admixed with liposomes
(Dietz and Vuk-Pavlovic , 1998; Tillman et al., 1999). It is not
entirely clear why Tillman et al. (1999) and Dietz and Vuk-
Pavlovic (1998) reported low transduction efficiencies with un-
modified adenovirus whereas Zhong et al. (1999) and Arthur
et al. (1997), among others, reported productive efficiencies ap-
proaching 95–100%  of human DCs. Concerns over initiation of
antiadenovirus immunity were generally not supported by in
vivo murine data. While adenovirus-infecte d human DCs could
prime an antiviral CTL response after several rounds of in vitro
stimulation (Butterfield et al., 1998; Perez-Diez et al., 1998),
mice immunized with adenovirus-infect ed DCs did not develop
significant antiviral CTLs (Brossart et al., 1997; Kaplan et al.,
1999). Furtherm ore, adenoviral immune mice could still be pro-
tected from tumor challenge by immunization with DCs in-
fected by adenovirus encoding TAA transgenes (Kaplan et al.,
1999). A paucity of antiadenoviral immunity after immuniza-
tion with adeno-infected DCs has also been reported by Wan
et al. (1997). While these results raise concerns that mice may
not represent a suitable model for studying in vivo effects of
adenovirus-infecte d DCs (possibly because of a reduced abil-
ity to mount an antiviral response compared with humans), these
disparate results may also represent differences arising from the
priming of CTLs in vitro versus in vivo . Collectively, it appears
that adenovirus (and possibly other viral vectors) represents an
efficient means for inserting transgenes into DCs without detri-
mental effects to its phenotype or function.
Tumor antigen gene-modified DCs capable of priming
antitumor immunity
The feasibility of gene modification of DCs to express TAA
was first reported by Alijagic et al. (1995). Using peripheral
blood monocytes cultured in GM-CSF and IL-4, these investi-
gators were able to transfect the resulting DCs with either a
chloramphenico l acetyl transferase (CAT) reporter gene or a
gene encoding human tyrosinase, a melanoma TAA. Gene
transfection (via cationic lipids) resulted in a fivefold increase
in CAT activity, while tyrosinase-transfe cted DCs elicited T
cell clustering and TNF-a release in an antigen-specific CTL
clone similar to that achieved using peptide-pulsed DCs (Ali-
jagic et al., 1995). However, neither transfection efficiency nor
the effect of transfection on DC phenotype and function (other
than activation of a long-term T cell clone) was determined.
Another approach to engineering DCs to express TAA was
demonstrated by Reeves et al. (1996), who utilized retroviral
transduction to deliver the MART-1 melanoma TAA. Since
retrovirus most efficiently introduces genes into actively cy-
cling cells, CD34 1 hematopoietic stem progenitor cells (HSCs)
as cycling DC precursors were chosen as targets. Using murine
CD86 as a marker for viral transfection, 20% transfection effi-
ciency, as determined by flow cytometric analysis of murine
CD86-expressi ng cells, resulted from infection of HSCs.
MART-1-expressing DCs were able to stimulate MART-1-
specific tumor-infiltratin g lymphocytes (TILs) in vitro. These
DCs could generate a MART-1-specific CTL response from au-
tologous peripheral blood mononuclear cells (PBMCs), sug-
gesting that like protein or peptide-pulsed DCs, genetically
modified DCs could initiate a specific antitumor T cell response.
In an attempt to improve the efficiency of transgene-
expressing DCs, pox and adenoviral vectors capable of directly
infecting DCs have been used to express TAA. Infection with
either a fowlpox or vaccinia viral vector encoding MART-1 re-
sulted in 50–75% MART-1-expressing DCs (Kim et al., 1997).
A single stimulation of peripheral blood lymphocytes (PBLs)
from some melanoma patients with MART-1 transgene-
expressing DCs but not with MART-1 peptide-pulsed DCs re-
sulted in antigen-specific IFN-g production and CTL genera-
tion. Full processing of the whole MART-1 protein and pre-
sentation by the DCs was confirmed by generation of CTLs
against multiple MART-1 epitopes. Other investigators using
an adenoviral vector encoding full-length MART-1 also re-
ported the generation of MART-1-specific CTLs by virally in-
fected DCs (Butterfield et al., 1998; Perez-Diez et al., 1998).
MART-1-expressing DCs (but not DCs infected with empty
vector) stimulated IFN-g production by CD4 1 and CD8 1 T
cells from many melanoma patients and healthy donors as mea-
sured by bulk enzyme-linked immunosorbent assay (ELISA)
and intracellular cytokine staining (Perez-Diez et al., 1998). In-
terestingly, no IL-4-producing T cells arose from coculture of
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MART-1-expressing DCs with bulk PBLs, suggesting a bias to-
wards generation of a helper T cell type 1 (Th1) response by
TAA gene-m odified DCs (Perez-Diez et al., 1998). TAA-
specific CTLs or IFN-g production could not be elicited by vi-
rally infected DC-stimulated peripheral blood in all melanoma
patients. Also of note, adenovirus-specif ic CTLs and IFN-g pro-
duction were present in PBL cultures after repeated stimulation
with adeno-infected DCs, raising a concern about the efficacy
of virally infected DCs in vivo (see above) (Butterfield et al.,
1998; Perez-Diez et al., 1998). With those caveats in mind,
however, these data suggest that DCs expressing a full-length
TAA protein were capable of processing and presenting TAA
via both the MHC class I and class II pathways and could elicit
superior T cell stimulation compared with peptide-pulsed DCs.
Mouse tumor models have been used to test the in vivo ther-
apeutic efficacy of TAA gene-modified DCs. Early efforts cen-
tered on tumor lines altered to express a model “tumor” anti-
gen such as b -galactosidase ( b -Gal) or ovalbumin (OVA) and
DCs expressing b -Gal or OVA transgenes (Brossart et al., 1997;
Song et al., 1997; Specht et al., 1997; Wan et al., 1997;
McArthur and Mulligan, 1998; De Veerman et al., 1999). Both
retroviral (Specht et al., 1997; De Veerman et al., 1999) and
adenoviral (Brossart et al., 1997; Song et al., 1997; Wan et al.,
1997; McArthur and Mulligan, 1998) transduction systems have
been used to insert genes encoding OVA or b -Gal into DCs de-
rived from bone marrow or splenic precursors or immortalized
DC lines. The resulting DCs generally showed no alterations in
phenotype as measured by flow cytom etric analysis of T cell
stimulatory molecules such as MHC I/II, CD80/CD86, and
ICAM-1 (De Veerman et al., 1999). Genetically modified DCs
were able to activate antigen-specific T cell lines in vitro
(Brossart et al., 1997; De Veerman et al., 1999), generate CTLs
in vivo (Brossart et al., 1997; Song et al., 1997; Specht et al.,
1997; Wan et al., 1997), and promote antitum or immunity in
both naive and tumor-bearing mice (Brossart et al., 1997; Song
et al., 1997; Specht et al., 1997; Wan et al., 1997; De Veerman
et al., 1999). In some studies peptide-pulsed and gene-
modified DCs were compared for their ability to initiate T cell
activation (both in vitro and in vivo) and antitumor immunity
(Brossart et al., 1997; Specht et al., 1997). DCs infected with
either an adenovirus or vaccinia virus encoding a CTL epitope
of OVA were equivalent to OVA protein or peptide-pulsed DCs
in their ability to activate an OVA-specific  CD8 1 T cell line,
prime OVA-specific CTLs from naive mice, and generate CTLs
on immunization in naive mice (Brossart et al., 1997). More
importantly, virally (either adenovirus or vaccinia) transduced
DCs generated protective antitumor immunity in both naive
mice or mice previously infected with the corresponding virus,
suggesting that antiviral immunity does not affect the efficacy
of transfected DCs, at least in mice. Using DCs generated from
retrovirally transduced bone marrow precursors, Specht et al.
(1997) showed that genetically engineered DCs could promote
therapeutic antitumor immunity in a metastatic model of 
disease. Treatment of day 3 lung metastases of a b -Gal-ex-
pressing CT26 colon carcinoma cell line was equally effective
in reducing tumor load using either peptide-pulsed or gene-
transduced DCs; however, gene-transduced DCs were more po-
tent primers of b -Gal CTLs in vivo . In another interesting mouse
model, NFSA murine fibrosarcoma cells engineered to express
the MART-1 human melanoma antigen were rejected in mice
immunized with DCs transfected with a MART-1 gene-encod-
ing adenovirus (Ribas et al., 1997). While these results are sug-
gestive, tumor cells expressing novel antigens are rendered
more immunogenic  compared with the parental cell line, which
poses the question of whether these results are due not to po-
tent antigen presentation by DCs but rather arise from the arti-
ficial nature of the tumor model per se.
To that end, studies have addressed the question of whether
DCs genetically engineered to express naturally occurring TAA
are capable of eliciting antitumor immunity in vivo . Tuting et
al. (1997) inserted a plasmid encoding wild-type p53 peptide
into bone marrow-derive d DCs via a particle bombardment  or
“gene gun” technique. This biolistic approach yielded a 5–10%
transfection efficiency and transgene expression lasting less
than 72 hr (Tuting et al., 1997). Nevertheless, immunization  of
naive mice with p53-transfected DCs resulted in protective im-
munity from a CMS4 sarcoma, which is known to overexpress
p53 (Tuting et al., 1997). However, CMS4 is a chemically in-
duced tumor, which is generally more immunogenic than nat-
urally arising tumors found in humans. In another mouse model,
immunization of naive mice with DCs transduced with an ade-
novirus encoding human p53 resulted in protection of . 70%
of mice challenged with tumors expressing human p53 or those
expressing mutated murine p53 (Ishida et al., 1999). Another
report has shown that DCs infected with adenoviral vectors en-
coding different TAA expressed by the murine melanom a line
B16 could elicit antitumor immunity to this naturally occurring
and poorly immunogenic tumor model (Kaplan et al., 1999). In
this study, DCs infected by adenovirus showed a 95% trans-
fection efficiency and no alterations in phenotype, with the ex-
ception of an increase in MHC class I expression. When ex-
pressed by DCs, target genes encoding CTL epitopes of
tyrosinase-related  protein 2 (TRP-2), or human gp100 (hgp100),
but not mouse gp100, elicited nearly complete protective im-
munity in immunized mice subsequently challenged with vi-
able tumor cells. Immunization  with TRP-2- and hgp100-ex-
pressing DCs could also slow the growth of recently implanted
tumors; combination of both TAA-expressing DCs further en-
hanced the antitumor effect. Although encouraging, established
tumors could not be completely eliminated after vaccination
with TAA-expressing DCs even though treatment began 4 days
after tumor challenge, before a palpable tumor arises (Kaplan
et al., 1999). This limitation may be due to the fact that only
CTL epitopes were encoded by the transgene and that the DCs
could not fully initiate CD41 T cell activation in the absence
of helper epitopes, a requisite for antitumor immunity (Toes et
al., 1999). These translational studies extend the in vitro data
using genetically modified human DCs to stimulate antitumor
immunity to well-characterize d animal models. The results to
date suggest that TAAs are suitable transgenes for use in im-
munotherapy protocols (Table 2). However, since most of these
models utilize artificially generated tumor antigens or treated
mice with small tumor loads (and did not result in curative treat-
ment), further modification of the system will need to be car-
ried out to improve therapeutic results.
Cytokine gene-modified DCs
Besides genetic modification to express TAA, DCs have
been successfully gene modified to express immunomodulatory
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proteins such as cytokines and chemokines (Table 3). One dis-
advantage in selecting TAA as a target gene for modification
of DCs is the tissue and MHC haplotype restriction of whole
tumor proteins and CTL epitopes, respectively. But DCs mod-
ified to express genes encoding T cell stimulatory cytokines,
for example, may be potentially used as adjuvants to treat any
number of tumors, so long as a source of TAA is available. Cy-
tokine gene-m odified DCs represent a potentially more potent
vaccine than similarly gene-modified tumor cells since the 
former are both APC and cytokine factories while the latter 
require host APC function (Tepper and Mulé, 1994).
In murine models of melanoma and sarcoma, IL-12 gene-
modified DCs injected directly into tumors induced a profound
antitumor response (Nishioka et al., 1999). While the amount
of tumor growth inhibition correlated with IL-12 production by
the DCs, the effect was dependent on DC stimulation of tumor-
specific immunity because IL-12 gene-modified fibroblasts in-
jected intratumorally had little effect on tumor growth (Nish-
ioka et al., 1999). Tuting et al. (1998) reported that IL-12
gene-m odified DCs could boost priming of TAA-specific  CD8 1
CTLs in vitro . In this study, DCs were genetically modified to
express different melanoma TAAs as well as either IL-12 or
IFN- a . IL-12 gene modification has also been shown to boost
CD4 1 T cell responses in infectious disease models. CD34 1
DCs derived from peripheral blood and retrovirally transduced
with genes to produce either IL-12 or IFN- g could augment
CD4 1 T cell-mediated cytokine production in response to bac-
terial antigens (Ahuja et al., 1998). Furthermore, immunization
of naive mice with IL-12 gene-modified DCs loaded with sol-
uble antigens from Leishmania donovani provided better pro-
tection from leishmaniasis than antigen-loaded unmodified DCs
(Ahuja et al., 1999). In both the mouse and human studies, 
IL-12 gene transfer led to DC maturation, as measured by in-
creased MHC class II and costimulatory molecule expression
(Tuting et al., 1998; Nishioka et al., 1999). Together, IL-12
gene modification of DCs could augment priming to antigens
delivered to DCs in a variety of manners and that these DC
could represent powerful adjuvants for activation of both CD4 1
helper T cells and CD8 1 CTLs.
Additional cytokine genes have been introduced into DCs
with the intent of increasing adjuvanticity. Retroviral infection
of PBMCs with an IL-7 gene construct followed by maturation
with GM-CSF plus IL-4 resulted in a DC population with in-
creased stimulatory capacity compared with untransfected cells
(Westermann et al., 1998). Presumably, the increased prolifer-
ation seen in allogeneic and autologous MLR was due to IL-7
enhancement of T cell proliferation. However, MLR assays do
not address how cytokine expression of DCs affects antigen-
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TABLE 2. TUM O R ANTIG EN GE NE-MOD IFIED DCS
Species Antigen (transfection vector) Comments References
Human Tyrosinase (liposomes) Transfected Dc-activated Ag-specific T cell line Alijagic et al. (1995)
MART-1 (viral vectors) Superior to peptide-pulsed DCs in eliciting CTLs Kim et al. (1997);
Primed CD4 1 and CD8 1 T cell response Butterfield et al. (1998);
Primed antiadenoviral CD8 1 T cell response Perez-Diez et al. (1998)
Multiple melanoma TAA Improved priming of CD81 T cell response by Tuting et al. (1998)
(gene gun) cotransduction with IL-12 or IFN-a
Mouse Ovalbum in, b -galactosidase, Immunization  promoted protection and therapeutic Brossart et al. (1997);
human MART-1 antitumor immunity Ribas et al. (1997); 
(viral vectors) Highly immunogenic model “tumor” antigen Specht et al. (1997)a
Human p53 (adenovirus) Protected mice from challenge with human p53- Tuting et al. (1997)
expressing tumors and mutant murine p53 tumors
Murine p53 (gene gun) Protected mice from challenge with CMS4 Ishida et al. (1999)
sarcoma
Tyrosinase-relat ed protein 2, Inhibited growth of established B16 melanom a Kaplan et al. (1999)
human gp100 
(adenovirus)
aSee text for complete references.
TABLE 3. CY TO KINE GE NE-MOD IFIED DEN DRIT IC CELLS
Cytokine Use of gene-modified DCs (species) References
GM-CSF Immunization for treatment of established tumors Cao et al. (1999); Curiel-Lewandrowski et al.
(mice) (1999)
Lymphotactin Immunization for treatment of established tumors Cao et al. (1999); Zhang et al. (1999)
(mice)
IL-12 In vitro priming of human T cells Ahuja et al. (1998); Tuting et al. (1998)
Intratumoral injection (mice) Nishioka et al. (1999)
Immunization against leishmaniasis (mice) Ahuja et al. (1999)
IL-7 In vitro stimulation of MLR in human PBLs Westermann et al. (1998)
Intratumoral injection (mice) Miller et al. (2000)
TABLE 4. CO M PA RISO NS OF TAA GEN E-MODIFIED DCS W ITH TAA PEPTID E-PULS ED DCS
Source of DCs Tumor antigen Results Reference
Adherent human PBMCs Tyrosinase: full-length gene Equal aggregation of DCs Alijagic et al.
cultured in versus tyrosinase with Ty-2- (1995)
GM-CSF 1 IL-4 peptide (Ty-2) specific T cell line
Adherent human PBMCs MART-1: full-length Increased IFN- g production Kim et al.
cultured in GM-CSF 1 IL-4 cDNA versus by CTLs raised (1997)
MART-127–35 peptide by gene-modified DCs
Murine bone marrow cells Ovalbumin: OVA257–264 Equivalent protective Brossart et al.
cultured in cDNA versus tumor immunity; (1997)
GM-CSF 1 IL-4 OVA257–264 peptide equivalent CTL generation
in vivo
Murine bone marrow cells b -Galactosidase:  full-length Equivalent protective tumor Specht et al.
cultured in GM-CSF 1 IL-4 LacZ cDNA versus immunity; superior (1997)
b -Gal876–884 peptide generation of IFN-g and 
CTLs in vitro
by gene-modified DCs
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specific or, more specifically, tumor antigen-specific T cell ac-
tivation. Further experimentation using antigen-specific CTL
assays and in vivo tests of therapeutic efficacy will be neces-
sary in order to determine if IL-7 gene modification represents
a significant improvem ent on DC-based vaccines. In this re-
gard, one report suggests that IL-7 gene-m odified DCs can me-
diate tumor regression through direct intratumoral injection
(Miller et al., 2000). Two reports suggest that modification of
DCs with another cytokine cDNA, GM-CSF, can increase ther-
apeutic antitumor immunity in vivo as compared with unmod-
ified DCs (Cao et al., 1999; Curiel-Lewandrowski et al., 1999).
However, the level of increased antitumor immunity varied be-
tween the two studies. In a protective immunity model of a
squamous cell carcinom a, 20% of mice immunized with lysate-
pulsed, GM-CSF gene-modified DCs (derived from GM-
CSF-cultured bone marrow cells) developed a tumor as opposed
to 100% of mice treated with unmodified but lysate-pulsed DCs
(Curiel-Lewandrowski et al., 1999). It was postulated that in-
creased survival of and migration by GM-CSF gene-modified
DCs were responsible for the increased antitumor immunity
(Curiel-Lewandrowski et al., 1999). However, in the B16
mouse melanoma model, GM-CSF-expressing splenic DCs
fused with tumor cells were only slightly (but not significantly)
more effective than unmodified DC/tumor fusions in both pro-
tecting mice from tumor challenge and increasing survival of
mice with established metastatic disease (Cao et al., 1999). It
is unlikely that this discrepancy is due to reported differences
in GM-CSF production as Cao et al. (1999) reported GM-CSF
levels in DC supernatants three to five times the levels reported
by Curiel-Lewandrowski et al. (1999). More likely, the differ-
ence resides in the tissue source of DCs because bone marrow-
derived DCs were shown previously to be more potent APCs
than splenic DCs and have increased antigen-processin g ca-
pacity (Fields et al., 1998). However, differences in tumor mod-
els and antigen loading may also explain these contradictory re-
sults, which may have potential significance for the design of
clinical protocols. Finally, DCs genetically engineered to se-
crete a T cell chemotactic factor, lymphotactin, and subse-
quently loaded with a peptide of the Mut1 TAA were found to
be potent stimulators of antitumor immunity against the 3LL
Lewis lung carcinoma (Cao et al., 1998). In this study, lym-
photactin gene-modified DCs were significantly more potent
than unmodified DCs. When tumor RNA was used as the source
of antigen, lymphotactin-se creting DCs were also superior to
untransfected DCs in the induction of antitumor immunity to
the B16 melanoma (Zhang et al., 1999), suggesting that this
chemokine could be applicable to a range of tumors and anti-
gen sources. Because of the emerging evidence that chemokines
play an important role in the priming of naive T cells by DCs
(Cyster, 1999), it is likely that future reports will describe the
modification of DCs with genes encoding other chemokines.
CONCLUSION
A number of studies have indicated that genetic modifica-
tion of DCs can improve their immunostim ulatory capacity and
provide an efficient means for antigen delivery to T cells. An-
imal tumor model data suggest that tumor antigen- and cytokine
gene-transfected DCs are equally capable and, in many cases,
superior APCs relative to unmodified DCs. It is premature at
this point to render a decision on whether TAA gene-modified
DCs represent a significant improvement in the development of
DC-based cancer vaccines since only four studies to date have
directly compared the efficacy of TAA gene-transduced DCs
with TAA peptide-pulsed counterparts (Table 4). The cumula-
tive results of these studies provide inconclusive evidence to
support the hypothesis that TAA gene-expressing DCs are su-
perior APCs relative to TAA peptide-pulsed DCs. Furthermore,
tumor lysate- or tumor RNA-pulsed DCs should be compared
with TAA gene-m odified DCs in order to determine if presen-
tation of a single TAA (via transgene expression) can induce
the same level of antitumor immunity as DCs expressing mul-
tiple TAAs. However, the results using cytokine gene-modified
DCs show, with few exceptions, a significant enhancement of
T cell priming and antitum or immunity. An important issue that
must still be addressed centers on the multitude of tissue cul-
ture protocols employed and different cellular sources from
which DC can be generated. Future work in this field should
involve determining optimal conditions and maturation factors
for gene-m odified DCs. An early indication of this effort comes
from a comparison of the timing of antigen pulsing and CD40
maturation in peptide and tumor RNA-loaded DCs (Morse et
al., 1998). The effect of CD40-mediated DC maturation on T
cell stimulation was found to be most effective when it occurred
after peptide pulsing but before loading with tumor RNA. It re-
mains to be seen what temporal restrictions apply to gene mod-
ification of DCs with regard to DC maturation protocols. Fi-
nally, the question of which target genes are ideally suited for
the clinic remains to be fully addressed. Because cytokine pro-
duction by DCs may enhance antitumor immunity against tu-
mors, it is conceivable that genes encoding cytokines IL-7 and
IL-12 or the chemokine lymphotactin may be the first to be
used in experimental DC-based vaccines in humans. However,
it is also likely that additional cytokines will be shown to aug-
ment DC priming of an antitumor response. Another, as yet
untested, avenue of research into gene-modified DCs involves
expression of T cell adhesion/ costimulatory molecules such as
B7 or ICAM-1 or DC survival receptors such as CD40 or
TRANCE-R. Just as the initial discovery of DC-mediated an-
titumor immunity prompted excitem ent for future therapeutics,
the early success of gene-modified DCs has engendered another
round of optim ism.
NOTE ADDED IN PROOF
Since the initial submission of this article, several reports
have described the use of genetically modified DC. Using retro-
virally transduced murine DC encoding full-length OVA pro-
tein or a class I MHC restricted epitope of OVA, Schnell et al.
(2000) provide evidence for a role of CD4 1 T cells in the gen-
eration of antitumor immunity against OVA-expressing tumors
but not for the initial generation of OVA-specific CTL. Immu-
nization of mice with DC genetically modified to express ei-
ther full-length human gp100 (Wan et al., 1999) or human
MART-1 (Ribas et al., 2000) can protect mice from a lethal
challenge of B16 melanoma cells (Wan et al., 1999). MART-
1 gene-modified human DC were equivalent to protein loaded
counterparts in their ability to stimulate MART-1 specific CTL
from melanom a patients (Philip et al., 2000). However, Oster-
roth et al. (2000) report that idiotype protein-pulsed DCs were
far superior to idiotype gene-modified DCs (via Semlike forest
virus) in inducing antigen-specific CTL from PBMC. Finally,
Jonuleit et al. (2000) report that infection of CD83 1 human DC
with adenoviral vectors leads to suppression of the allostimu-
latory capacity of DC.
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